IndexPharmaceuticals

InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för inflammatorisk tarmsjukdom som kan hjälpa patienter tillbaka till ett normalt liv.

[IndexPharmaceuticals @IndexPharmaAB]

Välkommen till InDex Pharmaceuticals Business Update-presentation i Stockholm den 9 maj, kl 13:00 till 15.30 CET https://t.co/89S5eyxmDx

[IndexPharmaceuticals @IndexPharmaAB]

Welcome to an InDex Pharmaceuticals business update presentation in Stockholm on May 9, from 13:00 to 15.30 CET https://t.co/G0XoF3tOZt

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) kallar till årsstämma https://t.co/j6iIKLkgfY

[IndexPharmaceuticals @IndexPharmaAB]

Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) https://t.co/O00WPH0mxk

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2022 https://t.co/gwjQGMfmYP

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2022 https://t.co/iAYeivGhNe

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals meddelar positiva resultat från en farmakokinetikstudie (PK-studie) med cobitolimod https://t.co/9WYtKEumLi

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod https://t.co/Dvli8ZfpI0

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals deltar i ECCO-kongressen 2023 https://t.co/YiGzEMG8VK

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals to attend the ECCO 2023 congress https://t.co/ySFkgR32Hr

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2022 https://t.co/UoZhQJKe84

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) year-end report 2022 https://t.co/CMcMw1NbcD

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals tillhandahåller kompletterande information om fas III-programmet CONCLUDE med cobitolimod https://t.co/AncTDUOHKH

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod https://t.co/Z22DOAzq4u

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod https://t.co/1NudnkShZO

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod https://t.co/Sa2bMLcpqJ

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) interim report January – September 2022 https://t.co/7Sp8gxLA0V

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2022 https://t.co/NWcZbbruHh

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2023 https://t.co/eGnnU9pltO

[IndexPharmaceuticals @IndexPharmaAB]

InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2023 Annual General Meeting https://t.co/KHQSYJuClw